Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS) Jaguar has received orphan drug designations for MVID & SBS in the US and EU Jaguar has also completed enrollment of pediatric MVID patients in an ongoing randomized clinical trial with plans for an NDA filing in mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of two late breaking abstracts for the treatment of pediatric IF from MVID and SBS at the 58th Annual Meeting of ESPGHAN. These pediatric IF patients are receiving liquid oral crofelemer as an investigational drug under two separate investigator-initiated trials.